EP Edge Journal Watch Issue 16: 11 New EP Trials on AF Ablation, SVT, Anticoagulation, PFA Safety, VT Pacing, and OHCA

In this episode of EP Edge Journal Watch , Dr. Sharma reviews 11 important new studies shaping modern cardiac electrophysiology, arrhythmia care, and cardiovascular risk management. This March 2026 issue covers intravenous amiodarone in preexcited atrial fibrillation , the NURSECAT-AF randomized trial of nurse-led care after AF ablation , left bundle branch area antitachycardia pacing vs right ventricular ATP , varenicline for ventricular ectopy after myocardial infarction , and the first clinical experience with reversible electroporation mapping in atrial flutter . The episode also examines abelacimab vs rivaroxaban in older patients with atrial fibrillation from AZALEA-TIMI 71 , device-assisted vs standard Valsalva for supraventricular tachycardia , the first reported case of severe pulmonary vein stenosis after pulsed field ablation , and the COBRRA trial comparing apixaban vs rivaroxaban bleeding risk in acute venous thromboembolism . Rounding out the issue are a nationwide analysis of out-of-hospital cardiac arrest on the first weekday after holidays and why the 2026 ACC/AHA multisociety dyslipidemia guideline matters directly to EP clinicians. This is a practical, evidence-focused review of where electrophysiology is heading: smarter AF care pathways, safer anticoagulation, better mapping, more physiologic pacing, improved SVT management, and a broader understanding of sudden cardiac risk . Full newsletter: EP Edge Journal Watch with references and infographics is available on LinkedIn as well as on Substack, epedge.substack.com . If you want, I can also make this into a shorter Transistor version , a more keyword-dense SEO version , or a more polished Apple/Spotify-style episode summary .